Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16217880 | 0.91 | RECQL (0.60) | RECQLGAAFAAHMEN1KMT2A | |
| SCHEMBL16250314 | 0.86 | RECQL (0.56) | RECQLGAAFAAHMEN1KMT2A | |
| SCHEMBL13203022 | 0.86 | RECQL (0.54) | RECQLGAAFAAHMEN1KMT2A | |
| SCHEMBL23587955 | 0.85 | RECQL (0.50) | RECQLGAAFAAHMEN1KMT2A | |
| SCHEMBL19477807 | 0.84 | RECQL (0.54) | RECQLGAAFAAHMEN1KMT2A | |
| SCHEMBL19477806 | 0.84 | RECQL (0.54) | RECQLGAAFAAHMEN1KMT2A | |
| SCHEMBL23079353 | 0.84 | RECQL (0.46) | RECQLGAAFAAHMEN1KMT2A | |
| SCHEMBL14894453 | 0.83 | FAAH (0.63) | RECQLGAAFAAHMEN1KMT2A | |
| SCHEMBL21698187 | 0.83 | FAAH (0.63) | RECQLGAAFAAHMEN1KMT2A | |
| SCHEMBL17640820 | 0.83 | RECQL (0.52) | RECQLGAAFAAHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | RECQL 3762/4885GAA 2127/4885FAAH 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.